Biora Therapeutics Receives Approval for First-in-Human BioJet Trial
Biora Therapeutics received approval for a first-in-human trial of its BioJet oral biologic delivery capsule.
Related stories
Neuronetics Q3 Revenue Reaches $41.962 Million
Neuronetics reported Q3 revenue of USD 41.962 million, versus the IBES estimate of USD 40.4 million.
M impact | EQUITY | Nov 04, 2026, 12:51 PM UTC
Neuronetics Reports Third-Quarter Loss per Share
M impact | EQUITY | Nov 04, 2026, 12:50 PM UTC
Neuronetics Reports Lower Q3 2026 Net Loss and Higher Revenue
M impact | EQUITY | Nov 04, 2026, 12:50 PM UTC
Neuronetics Reports Third-Quarter Revenue of $42M
M impact | EQUITY | Nov 04, 2026, 12:50 PM UTC
Datadog Reports Higher Third-Quarter Profit and Revenue
Datadog reported quarterly profit of $118.3 million, or 32 cents a share, with revenue also higher. The report attributes growth to continued platform adoption and increased custom
M impact | EQUITY | Nov 04, 2026, 12:50 PM UTC
Neuronetics Reports Third-Quarter 2026 Results
Neuronetics reported third-quarter 2026 financial and operating results.
M impact | EQUITY | Nov 04, 2026, 12:50 PM UTC